Literature DB >> 18181971

The levels of depression, anxiety and quality of life in patients with chronic idiopathic urticaria.

B Engin1, F Uguz, E Yilmaz, M Ozdemir, I Mevlitoglu.   

Abstract

BACKGROUND: Chronic idiopathic urticaria (CIU) is associated with severely impaired quality of life (QoL).
OBJECTIVE: To determine the levels of depression, anxiety and QoL in CIU patients. PATIENTS AND METHODS: This study included 73 patients with CIU, and 34 healthy subjects matched for age and sex were used as controls. The levels of depression, anxiety and QoL were assessed with the Beck Depression Inventory (BDI), the Beck Anxiety Inventory (BAI) and the World Health Organization Quality of Life Assessment-Brief (WHOQOL-BREF), respectively. The reliability and validity of the Turkish versions of these instruments have been examined.
RESULTS: When compared with healthy controls, patients with CIU had significantly higher BDI and BAI scores and significantly lower physical health and psychological health subscale scores of the WHOQOL-BREF. BDI, BAI and all domains of WHOQOL-BREF were unrelated to age, duration of illness, urticaria activity score (UAS) and visual analogue score (VAS). There was a negative significant correlation between all domains of WHOQOL-BREF and BDI and BAI.
CONCLUSION: Our data confirm that QoL is markedly reduced in CIU patients. Physical health and psychological health were found to be the areas QoL most affected in CIU patients. And also we have found that CIU patients frequently suffer from depression and anxiety. The severity of these parameters was found to be positively correlated with the extent of QoL decrease.

Entities:  

Mesh:

Year:  2008        PMID: 18181971     DOI: 10.1111/j.1468-3083.2007.02324.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  22 in total

1.  The impact of chronic idiopathic urticaria on quality of life in korean patients.

Authors:  Min Ju Kang; Hei Sung Kim; Hyung Ok Kim; Young Min Park
Journal:  Ann Dermatol       Date:  2009-08-31       Impact factor: 1.444

2.  The association of chronic spontaneous urticaria (CSU) with anxiety and depression: a nationwide cohort study.

Authors:  Dana Tzur Bitan; Daniella Berzin; Arnon Cohen
Journal:  Arch Dermatol Res       Date:  2020-04-08       Impact factor: 3.017

Review 3.  Histamine H2-receptor antagonists for urticaria.

Authors:  Zbys Fedorowicz; Esther J van Zuuren; Nianfang Hu
Journal:  Cochrane Database Syst Rev       Date:  2012-03-14

4.  [Chronic urticaria. Prevalence, course, prognostic factors and impact].

Authors:  K Weller; S Altrichter; E Ardelean; K Krause; M Magerl; M Metz; F Siebenhaar; M Maurer
Journal:  Hautarzt       Date:  2010-09       Impact factor: 0.751

5.  What'S new in urticaria?

Authors:  Sanjay Ghosh
Journal:  Indian J Dermatol       Date:  2009-07       Impact factor: 1.494

Review 6.  Current concepts in psychodermatology.

Authors:  Joseph A Locala
Journal:  Curr Psychiatry Rep       Date:  2009-06       Impact factor: 5.285

Review 7.  Safety and efficacy of desloratadine in subjects with seasonal allergic rhinitis or chronic urticaria: results of four postmarketing surveillance studies.

Authors:  Claus Bachert; Marcus Maurer
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

Review 8.  Role of biologics in intractable urticaria.

Authors:  Andrew Cooke; Adeeb Bulkhi; Thomas B Casale
Journal:  Biologics       Date:  2015-04-13

9.  Desloratadine for the Relief of Nasal and Non-nasal Allergy Symptoms: An Observational Study.

Authors:  Werner Aberer
Journal:  Arch Drug Inf       Date:  2009-06

10.  Diagnosis and treatment of urticaria and angioedema: a worldwide perspective.

Authors:  Mario Sánchez-Borges; Riccardo Asero; Ignacio J Ansotegui; Ilaria Baiardini; Jonathan A Bernstein; G Walter Canonica; Richard Gower; David A Kahn; Allen P Kaplan; Connie Katelaris; Marcus Maurer; Hae Sim Park; Paul Potter; Sarbjit Saini; Paolo Tassinari; Alberto Tedeschi; Young Min Ye; Torsten Zuberbier
Journal:  World Allergy Organ J       Date:  2012-11       Impact factor: 4.084

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.